Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
26 déc. 2019 08h00 HE
|
Innovation Pharmaceuticals, Inc.
Patient screening positions Company for completion of a short clinical trialSignificant market demand for oral drugs in Inflammatory Bowel DiseaseBusiness development meetings scheduled during 2020...
Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis
13 nov. 2019 08h30 HE
|
Innovation Pharmaceuticals, Inc.
Oral cancer incidence increasing worldwide due to spread of human papillomavirus (HPV), Oral SexMillions of patients worldwide suffer from treatment-induced Oral Mucositis (OM)Existing OM therapies...
Medifirst Solutions Provides Company Update for Its Oral Mucositis Treatment Studies
22 août 2019 10h38 HE
|
Medifirst Solutions
Freehold, NJ, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA...
IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology
01 mai 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 01, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent...
R-PHARM US Expands its Oncology Asset Portfolio with the Exclusive License and Distribution Rights to episil® in the United States
21 avr. 2016 08h00 HE
|
R-PHARM US, LLC
PRINCETON, N.J., April 21, 2016 (GLOBE NEWSWIRE) -- R-PHARM US today announced it has obtained the exclusive license and distribution rights to commercialize episil® oral liquid in the U.S....
FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis
07 mai 2015 16h42 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Sucampo Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608
07 août 2013 20h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (Sucampo) today announced the positive top-line results of two recently completed clinical trials, a Phase...